News & Updates

A self-controlled case series (SCCS) study conducted by the University of Hong Kong has found an increased risk of haemorrhagic stroke in recipients of mRNA BNT162b2 vaccine 14–27 days after the first dose and 0–13 days after the second dose, which is however lower than the incidence of haemorrhagic stroke within 28 days of confirmed SARS-CoV-2 infection.

Treatment with triheptanoin does not lead to a significant reduction in the frequency of seizures associated with glucose transporter 1 deficiency syndrome (Glut1DS), as shown in a study.

Treatment with intravenous ganaxolone induces rapid and durable seizure control in patients with refractory status epilepticus, while showing acceptable safety and tolerability, according to the results of an open-label phase II trial.

Large well-designed studies published in recent years point to an association of cerebral microbleeds (CMBs) with increased risks of intracerebral haemorrhage (ICH) and ischaemic stroke (IS). Although the association of CMBs with ICH is greater than with IS, the absolute incidence of IS is still higher than of ICH, implying that antithrombotics should not be routinely withheld for all patients with CMBs.

Cognitive changes in patients with chronic kidney disease (CKD) appear to correlate with accompanying changes in body mass index (BMI) and cerebral regional oxygen saturation (rSO2), reports a recent longitudinal study.

The combination of two targeted therapies, dabrafenib and trametinib, significantly improves the overall response rate (ORR) in paediatric patients with low-grade glioma (LGG) with BRAF V600 mutations compared with the combination of standard chemotherapy drugs, according to a study presented at ASCO 2022.

Some patients with benzodiazepine-refractory status epilepticus experience a toxin-related seizure, which can be successfully treated with a single dose of second-line antiseizure medication, according to a post hoc analysis of the Established Status Epilepticus Treatment Trial (ESETT).